Huahai Pharmaceutical Co., Ltd. and oncobiology Co., Ltd. jointly develop and sell four McAb biological drugs

On May 7, Huahai Pharmaceutical Co., Ltd., which is in the phase of public offering suspension, issued a notice, saying that the company has signed a strategic alliance, cooperative operation, joint venture operation, joint development and Technology License Agreement for biological drugs with oncology of the United States According to the agreement, Huahai Pharmaceutical Co., Ltd will enjoy 100% market license for the four McAb biological drugs signed in the agreement in the Chinese market; establish a joint venture in the United States to jointly develop the four McAb biological drugs, and Huahai Pharmaceutical Co., Ltd will enjoy 51% of the rights and interests of the above biological drugs in the markets of developed countries in Europe and the United States At the same time, the company will establish a biopharmaceutical company in China with oncobiologics to engage in the research and development of monoclonal antibodies and the application research of industrial technology The reporter inquired the website of oncologics and learned that oncologics has a team of nearly 100 scientists and R & D personnel, and has made a lot of achievements in the field of original biopharmaceutics and bio generic drugs Huahai Pharmaceutical Co., Ltd cooperates with oncobiologics in four monoclonal antibody generic drugs: adalimumab for rheumatoid, rituximab for non Hodgkin's lymphoma, avidin for lung cancer and rectal cancer, and Herceptin for breast cancer and rectal cancer These four McAb varieties are the top ten heavyweight varieties in the world According to the data, in 2012, the global sales of adalimumab was US $9.265 billion, that of rituximab was US $7.156 billion, that of avidin was US $6.150 billion, and that of Herceptin was US $6.283 billion Chen Baohua, general manager of Huahai pharmaceutical industry, told reporters that during the 13th Five Year Plan period starting in 2016, the global pharmaceutical industry will enter the era of bio generic drugs The spring of bio generic drugs such as monoclonal antibodies, diagnostic reagents, genes and target drugs has come It is reported that in 2012, the global monoclonal antibody market reached US $78 billion, and will maintain a compound growth rate of 44% per year In Chen Baohua's view, the research and development of monoclonal antibody bio generic drugs is quite difficult, mainly reflected in toxic side effects, amino acid sequencing, three-dimensional structure, biological specificity and other aspects For this reason, Huahai Pharmaceutical Co., Ltd has not only introduced the most high-end R & D team with the leader from the R & D team of gene tech, an international biopharmaceutical giant, but also established a high standard system to strive for precise intervention from a high starting point However, although the research and development of monoclonal antibody bio generic drugs is very difficult, its pricing is also very high - close to 70% of the original research drugs, which can be described as "high risk, high income" It can be said that in the future, biomedical business will become a new focus of Huahai pharmaceutical industry In the 2012 annual report, the company revealed that it will be involved in the field of monoclonal antibody biology and realize the business of new drug creation On the existing basis, it will enter the field of biology and new drugs from a high starting point through joint venture with internationally renowned research institutions and project transfer, making it a strong driving force for the company's rapid development in the future In fact, Huahai pharmaceutical's entry into the field of Biopharmaceutics can also be understood as the company's replication of the successful experience of the first transformation In 2003, Huahai pharmaceutical industry began to transform from a single API company to preparation Ten years later, the company's preparation business and API have achieved high growth "When we decided to transform into preparations, we decided to start at the high end and directly enter the U.S market When our R & D, technology and technology are recognized by the U.S market, it will be easier to attack overseas markets such as South America and Russia Huahai pharmaceutical industry should be a multinational company of international generic drugs " Chen Baohua said However, needless to say, the transformation of Huahai pharmaceutical industry is far more difficult than the previous one The four McAb imitations in the above cooperation agreement are still in the pre clinical stage, and it will take a long time for the products to go on the market.